MX2021003843A - Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer. - Google Patents
Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.Info
- Publication number
- MX2021003843A MX2021003843A MX2021003843A MX2021003843A MX2021003843A MX 2021003843 A MX2021003843 A MX 2021003843A MX 2021003843 A MX2021003843 A MX 2021003843A MX 2021003843 A MX2021003843 A MX 2021003843A MX 2021003843 A MX2021003843 A MX 2021003843A
- Authority
- MX
- Mexico
- Prior art keywords
- yap
- taz
- inhibitors
- cancer
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000003993 interaction Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Testing Relating To Insulation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La invención se refiere a compuestos de fórmula (I): (ver Fórmula) en donde R1, R2, R3, R4, R5 y (ver Fórmula) son como se define en la descripción.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306294.2A EP3632908A1 (en) | 2018-10-02 | 2018-10-02 | Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer |
| PCT/EP2019/076681 WO2020070181A1 (en) | 2018-10-02 | 2019-10-02 | Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021003843A true MX2021003843A (es) | 2021-05-27 |
Family
ID=63857833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003843A MX2021003843A (es) | 2018-10-02 | 2019-10-02 | Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11999758B2 (es) |
| EP (2) | EP3632908A1 (es) |
| JP (1) | JP7430715B2 (es) |
| KR (1) | KR20210072001A (es) |
| CN (1) | CN113039182B (es) |
| AU (1) | AU2019352009B2 (es) |
| BR (1) | BR112021006229A2 (es) |
| CA (1) | CA3114375A1 (es) |
| DK (1) | DK3860990T3 (es) |
| ES (1) | ES2931150T3 (es) |
| HU (1) | HUE059965T2 (es) |
| IL (1) | IL281999B2 (es) |
| MX (1) | MX2021003843A (es) |
| PL (1) | PL3860990T3 (es) |
| PT (1) | PT3860990T (es) |
| SI (1) | SI3860990T1 (es) |
| WO (1) | WO2020070181A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| JP2023544719A (ja) | 2020-09-30 | 2023-10-25 | カトリーケ・ユニフェルシテイト・ルーヴァン | がん治療のためのｙａｐ／ｔａｚ－ｔｅａｄ活性の阻害剤としての１，２，３，４－テトラヒドロキノリン誘導体 |
| AR125350A1 (es) | 2021-04-16 | 2023-07-12 | Orion Corp | Inhibidores tead |
| JPWO2023042901A1 (es) * | 2021-09-16 | 2023-03-23 | ||
| CN116239498B (zh) * | 2023-05-11 | 2023-07-21 | 北京元延医药科技股份有限公司 | 制备克立硼罗中间体的方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5306818A (en) | 1990-11-01 | 1994-04-26 | Sterling Winthrop Inc. | Tetrahydro 2-saccharinylmerthyl aryl carboxylates |
| US6200957B1 (en) | 1995-12-14 | 2001-03-13 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6011034A (en) | 1998-02-12 | 2000-01-04 | Uniroyal Chemical Company, Inc. | Insecticidal dihydrooxadiazine compounds |
| JP2005538118A (ja) | 2002-08-06 | 2005-12-15 | アストラゼネカ アクチボラグ | Ｔｉｅ２（ｔｅｋ）活性を持つ縮合したピリジン及びピリミジン |
| CA2520124A1 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of benzazole compounds for immunopotentiation |
| BRPI0617534A2 (pt) | 2005-09-23 | 2011-07-26 | Memory Pharm Corp | Composto, composição farmacêutica, método para a ativação/estimulação seletiva de receptores nicotínicos de a-7 em um paciente, método para o tratamento de um paciente que sofre de uma doença psicótica, uma doença neurodegenerativa que envolve uma disfunção do sistema colinérgico, e/ou uma condição de degeneração da memória e/ou da cognição, método para o tratamento de um paciente que sofre de demência e/ou uma outra condição com perda da memória, método para o tratamento de um paciente que sofre de degeneração da memória devida à degeneração cognitiva suave devida ao envelhecimento, mal de alzheimer, esquizofrenia, mal de parkinson, mal de huntington, mal de pick, mal de creutzfeldt-jakob, depressão, envelhecimento, trauma na cabeça, acidente vascular cerebral, hipoxia do cns, senilidade cerebral, demência de multiinfarto, hiv e/ou doença cardiovascular, método para o tratamento e/ou a prevenção da demência em um paciente com mal de alzheimer, método para o tratamento de um paciente para a retirada do álcool ou para o tratamento de um paciente com terapia anti-intoxicação, método para o tratamento de um paciente para conferir neuroproteção contra os danos associados com acidentes vasculares cerebrais e isquemia e excitotoxicidade induzida por glutamato, método para o tratamento de um paciente que sofre de vício de nicotina, dor, tontura de fuso horário, obesidade e/ou diabetes, método de indução de um paciente a parar de fumar, método para o tratamento de um paciente que sofre de degeneração cognitiva suave (mci), demência vascular (vad), declínio cognitivo associado com a idade (aacd), amnésia associada com a cirurgia de coração aberto, apreensão cardíaca, anestesia geral, déficits da memória devido à exposição a agentes anestésicos(...) |
| JO3598B1 (ar) * | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| US20100160424A1 (en) | 2007-06-20 | 2010-06-24 | Baldwin John J | Renin inhibitors |
| WO2009029998A1 (en) | 2007-09-06 | 2009-03-12 | Cytopia Research Pty Ltd | Retrometabolic compounds |
| JP5489235B2 (ja) | 2007-11-15 | 2014-05-14 | ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド | Ｎ含有複素環式化合物 |
| JP5578490B2 (ja) * | 2008-12-26 | 2014-08-27 | 味の素株式会社 | ピラゾロピリミジン化合物 |
| FR2942797B1 (fr) | 2009-03-03 | 2011-04-29 | Pf Medicament | Derives de benzothiazines, leur preparation et leur application a titre de medicaments |
| EP2397482A1 (en) | 2010-06-15 | 2011-12-21 | Almirall, S.A. | Heteroaryl imidazolone derivatives as jak inhibitors |
| CA2818623C (en) | 2010-12-21 | 2019-03-12 | Janssen Pharmaceutica Nv | Antifungal 5,6-dihydro-4h-pyrrolo[1,2-a][1,4]-benzodiazepines and 6h-pyrrolo[1,2-a][1,4]benzodiazepines substituted with bicyclic benzene derivatives |
| EP2592077A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| CN104053661B (zh) | 2011-11-23 | 2018-06-19 | 癌症研究技术有限公司 | 非典型性蛋白激酶c的噻吩并嘧啶类抑制剂 |
| WO2013123071A1 (en) | 2012-02-13 | 2013-08-22 | Cleave Biosciences, Inc. | Methods and compositions for jamm protease inhibition |
| EP2861570B1 (en) | 2012-06-19 | 2018-07-18 | Rutgers, The State University of New Jersey | Antibacterial agents: aryl myxopyronin derivatives |
| US9737522B2 (en) | 2012-08-09 | 2017-08-22 | Emory University | NMDA receptor modulators and uses related thereto |
| US8906929B2 (en) | 2012-08-16 | 2014-12-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| JP6211530B2 (ja) | 2012-11-19 | 2017-10-11 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| US9458124B2 (en) | 2013-02-06 | 2016-10-04 | Wayne State University | Substituted pyran derivatives |
| JP2016533385A (ja) | 2013-08-22 | 2016-10-27 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | アルキニルアルコール及び使用方法 |
| EP3086644A1 (en) * | 2013-12-23 | 2016-11-02 | Syngenta Participations AG | Benzoxaborole fungicides |
| CR20170118A (es) | 2014-10-08 | 2017-07-10 | Hoffmann La Roche | Derivados espirodiamina como inhibidores de la aldosterona sintasa |
| WO2016109559A2 (en) | 2014-12-29 | 2016-07-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof |
| JP6887996B2 (ja) * | 2015-09-23 | 2021-06-16 | ザ ジェネラル ホスピタル コーポレイション | Ｔｅａｄ転写因子自己パルミトイル化阻害剤 |
| EP3156404A1 (en) * | 2015-10-15 | 2017-04-19 | Inventiva | New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma |
| CN107709288A (zh) | 2016-02-03 | 2018-02-16 | 四川海思科制药有限公司 | 一种磷酰胺衍生物及制备方法和用途 |
| CN109912609A (zh) * | 2017-12-12 | 2019-06-21 | 江苏三月光电科技有限公司 | 一种以含氮五元杂环为母核的化合物及其在有机电致发光器件上的应用 |
-
2018
- 2018-10-02 EP EP18306294.2A patent/EP3632908A1/en not_active Withdrawn
-
2019
- 2019-10-02 US US17/278,429 patent/US11999758B2/en active Active
- 2019-10-02 BR BR112021006229A patent/BR112021006229A2/pt unknown
- 2019-10-02 HU HUE19782584A patent/HUE059965T2/hu unknown
- 2019-10-02 KR KR1020217011255A patent/KR20210072001A/ko active IP Right Grant
- 2019-10-02 IL IL281999A patent/IL281999B2/en unknown
- 2019-10-02 DK DK19782584.7T patent/DK3860990T3/da active
- 2019-10-02 WO PCT/EP2019/076681 patent/WO2020070181A1/en active Application Filing
- 2019-10-02 MX MX2021003843A patent/MX2021003843A/es unknown
- 2019-10-02 AU AU2019352009A patent/AU2019352009B2/en active Active
- 2019-10-02 CN CN201980075645.2A patent/CN113039182B/zh active Active
- 2019-10-02 SI SI201930344T patent/SI3860990T1/sl unknown
- 2019-10-02 ES ES19782584T patent/ES2931150T3/es active Active
- 2019-10-02 CA CA3114375A patent/CA3114375A1/en active Pending
- 2019-10-02 PT PT197825847T patent/PT3860990T/pt unknown
- 2019-10-02 EP EP19782584.7A patent/EP3860990B1/en active Active
- 2019-10-02 JP JP2021518089A patent/JP7430715B2/ja active Active
- 2019-10-02 PL PL19782584.7T patent/PL3860990T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020070181A1 (en) | 2020-04-09 |
| CA3114375A1 (en) | 2020-04-09 |
| EP3860990A1 (en) | 2021-08-11 |
| PL3860990T3 (pl) | 2023-01-23 |
| SI3860990T1 (sl) | 2022-11-30 |
| JP2022504077A (ja) | 2022-01-13 |
| BR112021006229A2 (pt) | 2021-07-06 |
| CN113039182A (zh) | 2021-06-25 |
| US11999758B2 (en) | 2024-06-04 |
| AU2019352009A1 (en) | 2021-04-15 |
| CN113039182B (zh) | 2024-02-20 |
| IL281999B1 (en) | 2023-11-01 |
| HUE059965T2 (hu) | 2023-01-28 |
| DK3860990T3 (da) | 2022-12-19 |
| ES2931150T3 (es) | 2022-12-27 |
| IL281999A (en) | 2021-05-31 |
| EP3860990B1 (en) | 2022-09-14 |
| AU2019352009B2 (en) | 2024-04-04 |
| IL281999B2 (en) | 2024-03-01 |
| US20210323982A1 (en) | 2021-10-21 |
| JP7430715B2 (ja) | 2024-02-13 |
| KR20210072001A (ko) | 2021-06-16 |
| PT3860990T (pt) | 2022-10-18 |
| EP3632908A1 (en) | 2020-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20200518A (es) | Piridozinonas como inhibidores de parp7 | |
| MX2021003843A (es) | Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer. | |
| CR20200393A (es) | Picolinamidas como fungicidas | |
| MX2022005216A (es) | Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7). | |
| MY196749A (en) | Eif4a-inhibiting compounds and methods related thereto | |
| MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| TN2018000119A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
| MX2020009234A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos. | |
| PH12021550382A1 (en) | Tetrahydropyridopyrimidine derivatives as ahr modulators | |
| EA201992320A1 (ru) | Пиперидины в качестве ковалентных ингибиторов менина | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| MX2021012501A (es) | Inhibidores de complejo represivo polycomb 2 (prc2). | |
| MX2022001004A (es) | Inhibidores de enzimas. | |
| PH12019550224A1 (en) | Antitumoral compounds | |
| WO2018035346A8 (en) | KINASE INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING CANCER | |
| MX2021001471A (es) | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). | |
| MX2020006434A (es) | Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor). | |
| MX2020007403A (es) | Compuestos de tetrahidroisoquinolina. | |
| MX2016016507A (es) | Composiciones y metodos para tratar canceres. | |
| MX2018008507A (es) | Inhibición de proteína relacionada con ataxia telangiectasia y rad3 (atr). | |
| ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
| MX2020006436A (es) | Compuestos inhibidores del blanco mecanistico de rapamicina (mtor). | |
| WO2019036417A3 (en) | Inhibition of ngly1 for the treatment of cancer | |
| EP3628374A3 (en) | Bcl-3 inhibitors |